New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
12:13 EDTWIN, CTL, FTR, MRK, PFE, UPS, MW, PGTI, GALTOn The Fly: Midday Wrap
Stocks on Wall Street were mixed at midday despite a much better than expected consumer confidence reading and better than expected earnings from two pharmaceutical giants. With the Fed currently conducting its two-day FOMC meeting, investors may be choosing to remain cautious ahead of tomorrow’s conclusion. The averages have weakened in the last hour and are now mixed, with the Nasdaq leading and the S&P 500 lagging, but all of the major averages are not far from their starting points. ECONOMIC EVENTS: In the U.S., the S&P Case Shiller home price index rose 9.34% from the prior year in May to 170.64, which was a bit below the expectation for a 9.9% year-over-year increase. The Conference Board's consumer confidence reading climbed to 90.9 in July from an upwardly revised 86.4 June figure, beating expectations for a 85.4 reading and reaching its highest level since October 2007. COMPANY NEWS: Windstream (WIN) jumped 12% and sent ripples throughout the telecom sector after announcing plans to spin off certain telecommunications network assets into an independent, publicly traded Real Estate Investment Trust, or REIT. Windstream confirmed it has received a private letter ruling from the Internal Revenue Service relating to certain tax matters regarding the tax-free nature of the spinoff and the qualification of the spunoff entity's assets as real property for REIT purposes. In addition to Windstream, shares of other companies that provide communications services gained as they were viewed as potentially being positioned to pursue similar plans, with Frontier Communications (FTR) advancing 11% and CenturyLink (CTL) rising 4%. However, Morgan Stanley cautioned that this ruling could reopen the political debate on REIT exemptions, especially if bigger companies begin to explore them, while UBS said large Telcos such as AT&T (T) and Verizon (VZ) are unlikely to consider a similar structural separation... UPS (UPS) fell 3.5% after reporting Q2 adjusted earnings per share that missed expectations and lowering its fiscal year earnings outlook, citing its plans to increase operating expenses for capacity and peak related projects to a total of $175M. “These initiatives will increase operating expense this year, but will provide financial benefits for years to come,” said UPS CFO Kurt Kuehn... Two Dow members and pharma giants, Pfizer (PFE) and Merck (MRK), both reported sales and profits that beat expectations for their second quarters. Pfizer, which backed its fiscal year adjusted EPS view but lowered its adjusted revenue view for the year, fell 0.4%, while Merck gained 1.6% near noon after its own report. MAJOR MOVERS: Among the notable gainers was windows and door supplier PGT Inc. (PGTI), which gained 28% after reporting better than expected quarterly results and agreeing to buy CGI Windows & Doors for about $111M. Among the noteworthy losers was Men's Wearhouse (MW), which fell 7% after the company gave long-term guidance during its analyst day meeting. Also lower was Galectin Therapeutics (GALT), which plunged 55% after the company posted a presentation on its website that contains a summary of the results of the second cohort of patients in the Phase 1 clinical trial for GT-020. Galectin's GR-MD-02 showed no difference from placebo across most efficacy biomarkers in the phase I study of nonalcoholic steatohepatitis, according to The Street's Adam Feuerstein. INDEXES: Near midday, the Dow was down 1.79, or 0.01%, to 16,980.80, the Nasdaq was up 8.00, or 0.18%, to 4,452.91, and the S&P 500 was down 1.91, or 0.1%, to 1,977.00.
News For WIN;CTL;FTR;MRK;PFE;UPS;MW;PGTI;GALT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 23, 2014
14:08 EDTUPSEarnings Preview: UPS sentiment mixed ahead of Q3 report
United Parcel Service (UPS) is expected to report third quarter earnings on Friday, October 24, before the market open with a conference call scheduled for 8:30 am ET. UPS is a package delivery company and provider of global supply chain management solutions. EXPECTATIONS: Analysts are looking for earnings per share of $1.29 on revenue of $14.2B, according to First Call. The consensus range for EPS is $1.24-$1.35 on revenue of $14.01B-$14.41B. LAST QUARTER: UPS reported second quarter adjusted EPS of $1.21 against estimates for $1.25, on revenue of $14.27B against estimates for $14.1B. On its Q2 report, the company lowered its fiscal 2014 adjusted EPS view to $4.90-$5.00 from the "low end" of the $5.05-$5.30 range, compared to consensus of $5.09. The company announced plans to increase 2014 operating expense for capacity and peak related projects to a total of $175M. CFO Kurt Kuehn said, "These initiatives will increase operating expense this year, but will provide financial benefits for years to come." On its Q2 conference call, management said it would treat Black Friday as a full operating day this year. They expect a "very strong" peak season and said "all options are on the table" going forward after they evaluate their peak season performance, including consideration of a surcharge. STREET RESEARCH: Street research has been mixed in the weeks leading up to UPS’s Q3 earnings report. On July 30 Bernstein said weakness in UPS shares was overdone following its Q2 report. Bernstein remained encouraged by the company's U.S. margins and volume growth. It viewed the stock as undervalued and kept an Outperform rating on the shares. On July 31, Atlantic Equities downgraded UPS to Neutral from Overweight. On September 26, Argus said UPS weakness created a buying opportunity. Argus noted that UPS had already begun hiring temporary workers and building remote villages ahead of the 2014 holiday shopping season. The firm thought the company will benefit from these extra workers into 2015, and it expects the company to benefit from a number of positive trends. It said the stock has a fair value of $115 and kept a Buy rating on the shares. PRICE ACTION: UPS shares have traded modestly higher since Q2 results were released. The stock has gained over 7% over the past twelve months. In afternoon trading ahead of Friday's Q3 report, UPS shares are up more than 1.8%.
08:15 EDTPFEPfizer wins SUTENT patent case In Delaware District Court
Pfizer (PFE) announced today that the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering SUTENT capsules. This decision, which is subject to appeal, affirms Pfizer’s right to exclusively provide sunitinib malate as SUTENT to patients through the term of the patent, which expires in 2021. Pfizer filed suit in June 2010 after Mylan (MYL) applied to the U.S. Food and Drug Administration to market a generic version of SUTENT prior to the expiration of the patents covering sunitinib malate and its uses. After a four-day trial, the Court agreed that Mylan infringed the valid patents covering SUTENT.
October 22, 2014
10:24 EDTUPSUPS October weekly volatility elevated into Q3 and outlook
Subscribe for More Information
07:35 EDTMRKCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
October 21, 2014
09:01 EDTCTLCenturyLink and Switch SUPERNAP announce strategic agreement
Subscribe for More Information
07:15 EDTPFEFDA to hold workshop on breast cancer drug development
Subscribe for More Information
07:06 EDTPFEFierce Biotech to hold a breakfast meeting
Subscribe for More Information
October 20, 2014
17:26 EDTMWSAB Capital Advisors reports 5.1% passive stake in Men's Wearhouse
Subscribe for More Information
16:39 EDTUPSUPS 2015 rates for ground, air, international,freight, air freight to be up 4.9%
UPS released new published rates for 2015. UPS Ground, Air, International, UPS Freight, and UPS air freight rates within and between the U.S., Canada, and Puerto Rico will increase an average of 4.9%. The increase is effective Dec. 29.
08:06 EDTMRKMerck, Sanofi unit announce pediatric hexavalent vaccine BLA
Subscribe for More Information
07:47 EDTPFEPfizer less likely to renew Astra pursuit after Shire deal breakdown, FT says
Subscribe for More Information
07:34 EDTMRKAdvaxis names Mauro Chief Medical Officer
Advaxis (ADXS) announced that it has appointed David Mauro, as executive vice president, Chief Medical Officer Mauro most recently served as executive director, section head oncology clinical development at Merck (MRK). In connection with his appointment, Mauro received a one-time inducement award of 165K restricted shares, of which 55K are fully vested and as of the grant date. The remaining shares vest annually over a two-year period.
07:19 EDTMRKIBC Life Sciences to hold a conference
Subscribe for More Information
07:15 EDTPFEAmerican Academy of Child & Adolescent Psychiatry to hold annual meeting
Subscribe for More Information
07:12 EDTPFECongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
07:11 EDTPFE, MRKAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTPFEAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 17, 2014
16:41 EDTPFEPfizer confirms FDA labeling approval for EMBEDA capsules
Pfizer announced that the FDA has approved an updated label for EMBEDA extended-release capsules, for oral use to include abuse-deterrence studies. The updated label states that EMBEDA has properties that are expected to reduce abuse via the oral and intranasal routes when crushed. However, abuse of EMBEDA by these routes is still possible. The updated label also includes data from a human abuse potential study of intravenous, or IV, morphine and naltrexone to simulate crushed EMBEDA. However, it is unknown whether the results with simulated crushed EMBEDA predict a reduction in abuse by the IV route until additional postmarketing data are available. EMBEDA is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Pfizer expects EMBEDA will be available in the U.S. in early 2015.
16:30 EDTPFEFDA approves new labeling from Embeda extended-release capsules
Subscribe for More Information
07:58 EDTMRKDeutsche Bank specialty pharma analyst holds analyst/industry conference call
Specialty Pharmaceuticals Analyst Gilbert provides of preview of The Improved Reduction of Outcomes: Vytorin Efficacy Internal Study (IMPROVE-IT) on an Analyst/Industry conference call to be held on October 17 at 10 am.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use